Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,614.62
(
0.44%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 224824

Tuesday, 07/30/2019 4:57:57 PM

Tuesday, July 30, 2019 4:57:57 PM

Post# of 257302
GILD 2Q19 HCV sales=$842M—including an $80M true-up adjustment in EU not related to actual sales in 2Q19. US HCV sales were $355M, and ex-US HCV sales $487M (including the $80M adjustment mentioned above).

Excluding the $80M true-up adjustment, 2Q19 HCV sales were $762M, -7% QoQ/-24% YoY.

PR:
http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-second-quarter-2019-financial-results

CC slides:
http://investors.gilead.com/static-files/607d8b95-08a2-4816-9ef5-8504dfcfc34e

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today